We've spent 25 years on both sides of that line — building the medical device, then carrying it through manufacturing, safety, and regulatory approval to market.
We lived through the wins and the failures.
Sachin Mamidwar, MD, MS, FAIMBE
Founder, Panacea Medical Consultants
Medical product development is neither easy, fast, nor cheap. Thousands of materials, composites, and designs fail before one succeeds. But when you develop a product that treats a condition — that lets a patient walk, eat, breathe, or simply live comfortably again — the whole long process becomes worth it.
Bone grafting has been done for decades, for patients who lose bone to cancer, infection, fracture, or accident. Every existing option carries a disadvantage: degradation that's too slow or too fast, acidic byproducts, risk of disease transmission. Even growth-factor products rely on too much BMP-2 because of poor release kinetics.
So we set out to build something better — fully synthetic, available in unlimited quantity, degrading at the rate bone grows and eventually disappearing completely, releasing growth factor and antibiotics in a controlled way over time. After many iterations and many failures, we developed a nanotechnology-based material that does all of it.
Leading that work is one of the most fulfilling experiences of my career. It's why I'd rather join a project at the beginning than clean up after it.
Not every medical device that works on the bench becomes a product. Manufacturing won't scale. The device is unusable in a clinician's hands. The regulatory pathway costs more than the company has. Or the evidence regulators want was never generated, because nobody asked for it early enough.
Development often runs ad hoc. When something works, no one can fully explain why — so it can't be reproduced, and it can't be scaled. When something fails, the lesson is lost.
We've spent 25 years on both sides of that line: building the medical device, and then carrying it through manufacturing, safety, and regulatory approval to market. We know where products die.
Most teams ask these in sequence — and discover the answer to question three after the design is already frozen. I ask all four from day one.
The science holds up — reproducibly, not once.
It survives manufacturing scale-up, and it's usable by the person who has to hold it.
The evidence regulators will ask for is generated by design, not reconstructed under deadline.
Safety, biocompatibility, and performance data that stand up to a reviewer — and to the market after launch.
Stuck on any of them? That's where I come in — I can help.
Years of hands-on experience across global medical device regulatory frameworks.
Every document accurate, comprehensive, and regulator-ready.
From strategy to writing to submission — your extended regulatory team.
Offices in India and the US, serving clients across North America, Europe, and Asia.
Including me. If someone doesn't clear this bar, keep looking.
From a single regulatory document to end-to-end submission support — the work clients most often bring to us.
The most expensive regulatory work is the work you do twice. Biocompatibility, safety, radiation, sterility — every one of these is cheap to design for and brutal to retrofit. The teams that clear fastest aren't the ones with the best writers. They're the ones who knew what the file would need while the design was still soft.
Read more ›I once worked with a company that came to us for regulatory work on a cancer-detection device. Partway in, we had to tell them the truth: they didn't have a product yet. They had a technology, and they were years from the other thing. Telling a client that costs you the invoice and earns you the relationship.
Read more ›Large parts of clinical evaluation writing can and should be automated — I'm helping build exactly that kind of tooling. But automation produces output, not judgment. Someone still has to know whether the evidence is sufficient, whether the argument holds, and what a reviewer will push on. That part isn't going anywhere.
Read more ›Nearly everyone in this field started inside a regulatory department or at the agency, then went independent. I came from R&D and product development and moved toward regulatory. It's an unusual direction of travel, and it changes what I see: not just what the submission requires, but whether the science underneath it will actually hold.
Read more ›Companies with no prior presence in medical devices are now building them — AI systems that draft clinical notes, read scans, and recommend doses for critically ill patients. They're superb at software and new to regulation. That gap is where I've spent the last several years, and it's the fastest-moving corner of this field.
Read more ›“Working with Panacea Medical Consultants to establish our Quality Management System was a game-changer for our organization. Panacea delivered far more than a binder of generic templates. They took the time to understand our specific product risks, mapped our operational workflows, and helped us implement practical, scalable standard operating procedures that our team could actually use. Their deep regulatory expertise and hands-on guidance transformed our compliance posture and gave us total confidence heading into our certification audits. Thanks to their partnership, we were able to get a successful QMS that enabled our company to access various markets.”
“Regulatory approvals are a major bottleneck in our industry, and for five years Panacea has taken that friction out for us. They pair deep expertise with real thoroughness — anticipating authority concerns up front — so our submissions clear swiftly and save us time and resources.”
“Engaging Panacea from the very start of our patented device project was a game-changer. Their foresight kept every file current in real time and prevented costly backtracking during development, so when we submitted, our documentation was flawless. They handle the compliance, so we can focus on engineering.”
That's the conversation I want. Tell me where you are and what's in the way.
Start a conversation